Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 1/20 | 0.46 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | GRM8 | O00222 | 2/20 | 0.41 |
| ▸ | GRM6 | O15303 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029829 | 1.00 | SLC6A12 (0.46) | SLC6A12SLC6A11GRM4CYP1A2CYP2C19 | |
| SCHEMBL4452499 | 1.00 | SLC6A12 (0.46) | SLC6A12SLC6A11GRM4CYP1A2CYP2C19 | |
| SCHEMBL10331842 | 0.88 | SLC6A12 (0.44) | SLC6A12SLC6A11GRM4CYP1A2CYP2C19 | |
| SCHEMBL9141620 | 0.73 | GRM4 (0.34) | SLC6A12SLC6A11GRM4CYP1A2CYP2C19 | |
| SCHEMBL22941787 | 0.73 | GRM4 (0.34) | SLC6A12SLC6A11GRM4CYP1A2CYP2C19 | |
| SCHEMBL27607943 | 0.73 | GRM4 (0.35) | SLC6A12SLC6A11GRM4CYP1A2CYP2C19 | |
| SCHEMBL3580179 | 0.72 | SLC1A2 (0.38) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL76019 | 0.72 | GRM4 (0.37) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL5925394 | 0.72 | GRM2 (0.33) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL15440623 | 0.72 | GRM4 (0.37) | GRM4CYP1A2CYP2C19GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160109445-A1 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS | FIRMENICH INCORPORATED | 2016-04-21 | — | — | US | claimed |
| US-20140302528-A1 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS | SENOMYX, INC. (US) | 2014-10-09 | — | — | US | claimed |
| CN-103597071-A | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS INC | 2014-02-19 | — | — | CN | claimed |
| EP-2661266-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | claimed |
| US-20120015378-A1 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS | SENOMYX, INC. | 2012-01-19 | — | — | US | claimed |
| US-8030008-B2 | For use in foods, beverages, cosmetics and drugs | SENOMYX, INC. (US) | 2011-10-04 | — | — | US | claimed |
| US-20110136112-A1 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS | FIRMENICH INCORPORATED | 2011-06-09 | — | — | US | claimed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | claimed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | claimed |
| CN-101583717-A | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators | SENOMYX INC (US) | 2009-11-18 | — | — | CN | claimed |
| EP-2078081-A2 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS | Senomyx, Inc. (US) | 2009-07-15 | — | — | EP | claimed |
| US-20080187936-A1 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS | SENOMYX, INC. (US) | 2008-08-07 | — | — | US | claimed |
| WO-2008057470-A2 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS | SENOMYX, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| US-20080038739-A1 | For use in foods, beverages, cosmetics and drugs | SENOMYX, INC. (US) | 2008-02-14 | — | — | US | claimed |
| CN-119816487-A | FC conjugates comprising CD73 inhibitors and uses thereof | 奇达拉治疗公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119053336-A | Compositions and methods for treating autoimmune disorders | 密执安大学评议会 | 2024-11-29 | — | — | CN | disclosed |
| WO-2002036616-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002026818-A2 | HUMAN NEDD-1 | AEOMICA, INT. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002024718-A1 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |